Safety and Hemostatic Efficacy of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated (FS VH S/D) Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery
Evaluation of the Topical Hemostatic Efficacy and Safety of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery
Sponsor: Baxter Healthcare Corporation
This PHASE3 trial investigates Cardiac Surgery Requiring Cardiopulmonary Bypass and Median Sternotomy and Cardiopulmonary Bypass and is currently completed. Baxter Healthcare Corporation leads this study, which shows 7 recorded versions since 2002 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
May 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — May 2017 [monthly]
Completed PHASE3
First recorded
Sep 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baxter Healthcare Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ann Arbor, United States, Atlanta, United States, Boston, United States, Camden, United States, Charlottesville, United States, Chicago, United States, Cincinnati, United States, Cleveland, United States, Dallas, United States, Durham, United States and 12 more location s